Product Description
Casopitant is a novel NK1 receptor antagonist and second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant has now completed phase III trials for prevention of CINV. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Oncology Unspecified|Other|Colorectal Cancer|Lung Cancer
Phase 2: Depressive Disorder, Major|Insomnia|Spinal Cord Injuries|Enuresis|Overactive Bladder|Urinary Incontinence|Anesthesia Related|Other|Oncology Unspecified|Fibromyalgia|Dyspepsia
Phase 1: Healthy Volunteers|Oncology Unspecified|Kidney Diseases|Phobia, Social
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00891761 |
NCT00891761 | P3 |
Withdrawn |
Lung Cancer |
2010-07-01 |
2024-10-16 |
||
NCT00601172 |
NKV110721 | P3 |
Completed |
Colorectal Cancer |
2009-04-13 |
2024-10-16 |
Primary Endpoints|Treatments |
|
2007-005169-36 |
2007-005169-36 | P3 |
Completed |
Colorectal Cancer |
2009-04-07 |
2022-03-12 |
Treatments |
|
NCT00358813 |
NKT102783 | P1 |
Completed |
Kidney Diseases |
2008-08-22 |
2019-03-21 |
Treatments |
|
NCT00440128 |
NKV100781 | P1 |
Completed |
Oncology Unspecified |
2008-07-17 |
2019-03-21 |
Treatments |
|
NCT00431236 |
NKV102551 | P3 |
Completed |
Oncology Unspecified |
2007-10-09 |
2024-10-16 |
||
2006-002033-21 |
2006-002033-21 | P3 |
Completed |
Oncology Unspecified |
2007-10-09 |
2022-03-12 |
Treatments |
|
NCT00366834 |
NKV102549 | P3 |
Completed |
Other |
2007-10-01 |
2024-10-16 |
||
NCT00511823 |
NKV110483 | P1 |
Completed |
Healthy Volunteers |
2007-09-21 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT00460707 |
NKV109990 | P1 |
Completed |
Healthy Volunteers |
2007-08-27 |
2019-03-21 |
Treatments |
|
2006-000781-37 |
2006-000781-37 | P3 |
Completed |
Other |
2007-08-24 |
2025-07-09 |
Treatments |
|
2005-004889-17 |
2005-004889-17 | P2 |
Completed |
Insomnia |
2007-07-13 |
2022-03-12 |
Treatments |
|
NCT00354809 |
MAD105516 | P2 |
Completed |
Insomnia |
2007-07-01 |
2019-03-21 |
Treatments |
|
2006-001877-13 |
2006-001877-13 | P2 |
Terminated |
Depressive Disorder, Major |
2007-06-24 |
2022-03-12 |
Treatments |
|
NCT00437229 |
NKV100787 | P1 |
Completed |
Healthy Volunteers |
2007-05-15 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT00404274 |
NKV105097 | P1 |
Completed |
Healthy Volunteers |
2007-03-18 |
2019-03-21 |
Treatments |
|
NCT00280436 |
MAD105514 | P2 |
Completed |
Insomnia |
2007-03-01 |
2019-03-21 |
Treatments |
|
NCT00321477 |
NKB105022 | P2 |
Completed |
Enuresis|Urinary Incontinence|Overactive Bladder |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00280423 |
MAD103894 | P2 |
Completed |
Insomnia |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00332319 |
NKB104846 | P2 |
Terminated |
Enuresis|Overactive Bladder|Urinary Incontinence|Spinal Cord Injuries |
2007-02-01 |
2019-03-21 |
Treatments |
|
2005-001010-41 |
2005-001010-41 | P2 |
Terminated |
Fibromyalgia |
2007-01-11 |
2022-03-12 |
Treatments |
|
NCT00405080 |
Casopitant | P1 |
Completed |
Healthy Volunteers |
2007-01-05 |
2019-03-21 |
||
NCT00404378 |
GW679769 | P1 |
Completed |
Healthy Volunteers |
2007-01-05 |
2019-03-21 |
Treatments |
|
2005-005855-16 |
2005-005855-16 | P3 |
Completed |
Unknown |
2006-11-20 |
2022-03-12 |
Treatments |
|
NCT00359177 |
NKT102785 | P1 |
Completed |
Healthy Volunteers |
2006-10-12 |
2019-03-21 |
Treatments |